Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran
| Autor: | Aghigh koochak, Babak Bahar, Mohammad Hadi Karbalaie Niya, Mohammad Reza Babaee, Fahimeh Safarnezhad Tameshkel, Farid Imanzade, Masoudreza Sohrabi, Hossein Ajdarkosh, Mohammad Reza Khonsari, Gholamreza Hemmasi, Farhad Zamani, Nasser Rakhshani, Hamid Rezvani |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Proto-Oncogene Proteins B-raf 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Mutation rate endocrine system diseases Epidemiology Colorectal cancer DNA Mutational Analysis Iran medicine.disease_cause Bioinformatics High Resolution Melt Proto-Oncogene Proteins p21(ras) 03 medical and health sciences 0302 clinical medicine Mutation Rate Internal medicine Genotype Biomarkers Tumor Carcinoma medicine Humans neoplasms Neoplasm Staging Mutation business.industry Public Health Environmental and Occupational Health Middle Aged Prognosis medicine.disease Adenocarcinoma Mucinous digestive system diseases Cross-Sectional Studies 030104 developmental biology Lymphatic Metastasis 030220 oncology & carcinogenesis Adenocarcinoma Female KRAS Neoplasm Grading Colorectal Neoplasms business Carcinoma Signet Ring Cell Follow-Up Studies |
| Zdroj: | Asian Pacific Journal of Cancer Prevention. 17:603-608 |
| ISSN: | 1513-7368 |
| DOI: | 10.7314/apjcp.2016.17.2.603 |
| Popis: | Background: The investigation of mutation patterns in oncogenes potentially can make available a reliable mechanism for management and treatment decisions for patients with colorectal cancer (CRC). This study concerns the rate of KRAS and BRAF genes mutations in Iranian metastatic colorectal cancer (mCRC) patients, as well as associations of genotypes with clinicopathological features. Materials and Methods: A total of 1,000 mCRC specimens collected from 2008 to 2012 that referred to the Mehr Hospital and Partolab center, Tehran, Iran enrolled in this cross sectional study. Using HRM, Dxs Therascreen and Pyrosequencing methods, we analyzed the mutational status of KRAS and BRAF genes in these. Results: KRAS mutations were present in 33.6% cases (n=336). Of KRAS mutation positive cases, 85.1% were in codon 12 and 14.9% were in codon 13. The most frequent mutation at KRAS codon 12 was Gly12Asp; BRAF mutations were not found in any mCRC patients (n=242). In addition, we observed a strong correlation of KRAS mutations with some clinicopathological characteristics. Conclusions: KRAS mutations are frequent in mCRCs while presence of BRAF mutations in these patients is rare. Moreover, associations of KRAS genotypes with non-mucinous adenocarcinoma and depth of invasion (pT3) were remarkable. Keywords |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|